We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
My link to Nottingham is dated March 19th the day after SNG001 was granted the trial.
A professor at the University of Nottingham has spoken of the potential benefits of an inhaled drug due to be trialled in the fight to treat coronavirus.
It's been confirmed that patients from Nottingham can be recruited into the trial which could start in the next few days
Prof Ian Hall, professor of molecular medicine at the university, who is a respiratory physician at the Queen’s Medical Centre, said it would involve administering a drug called “interferon beta”.
He described this as “a molecule which forms part of the lungs' own defence mechanism to fight off viruses”.
"The idea behind the trial is that, by giving more of this molecule to the lung, this could help reduce the severity of infection with Covid-19, especially in those people who have reduced immune responses to the virus," said Prof Hall.
He said the trial could potentially start in the next few days.
Prof Hall told Nottinghamshire Live: “If it did work it would potentially mean that patients who might otherwise need to go to intensive care might have a less severe disease and wouldn’t need to go to intensive care.”
Researchers in Southampton are conducting the trial and Nottingham University Hospitals have confirmed that they have joined and local patients can be included in it.
https://www.nottinghampost.com/news/nottingham-news/nottingham-professor-potential-benefits-drug-3964958
Thx xyz,
"To boost the potential effectiveness of ritonavir and lopinavir, one trial is testing a combination of those two drugs and interferon-beta, a compound doctors use as first-line therapy in the treatment of multiple sclerosis.
The trial — called MIRACLE — is currently testing this experimental treatment with the consent of MERS patients.
Yet another upcoming trial — supported by a U.K.-based pharmaceutical company and not part of the WHO effort — aims to use a specific formulation of interferon-beta on its own in the treatment of COVID-19.
“The idea behind the trial is that, by giving more of this molecule to the lung, this could help reduce the severity of infection with COVID-19, especially in those people who have reduced immune responses to the virus,” explains Prof. Ian Hall from the University of Nottingham in the U.K. Prof Hall is not associated with the upcoming trial." - Cohut, M . (2020) Extract from article 26.3.20 Medical News Today
???
yeah, that's what Id read before I found this
(https://www.medicalnewstoday.com/articles/who-launch-trial-testing-4-potential-covid-19-treatments#Antiretrovirals-and-interferon-beta)
IV would be ineffective due to half life drug. SNG001 is dosed directly to the lungs where it is needed.
sorry, link no good......was Medical News Today website; 'WHO launch trial testing 4 potential COVID-19 treatments'
Yeah you are wrong
BTW - this is where I read it today -thx
https://www.medicalnewstoday.com/articles/who-launch-trial-testing-4-potential-covid-19-treatments
nice post Maqs the real deal here
SNG001 is one of WHOs four preferred treatments which are on trial stage.
Thought I read today ( art. dated 26.3 ) that WHO's Solidarity 4th trial seemed to include just IV delivery methods of beta-interferon ? Looks like inhaled versions weren't included? Is this correct and if so, any idea why ? If correct, I wondered if this could be because it is already a planned trial or that they chose / mutually agreed not to be included (eg. perhaps as the WHO criteria didn't fit the planned trial) ? Just wondered if anyone here can shed light / correct me / may even be outdated now ?